Search research articles
Contact Us
Filters
Showing results (31-40 of 103) with videos related to
Page
of 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2004
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma
Brian H Kushner, Kim Kramer, Michael P LaQuaglia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2003
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy
Brian H Kushner, Samuel D J Yeh, Kim Kramer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2014
Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission
Brian H Kushner, Irene Y Cheung, Shakeel Modak, et al.
Cancer
|
July 13, 2002
Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8
Irene Y Cheung, M Serena Lo Piccolo, Nancy Collins, et al.
Oncoimmunology
|
June 27, 2013
Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-<i>D</i>-glucan: A Phase I study in patients with chemoresistant neuroblastoma
Shakeel Modak, Brian H Kushner, Kim Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2003
Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma
Irene Y Cheung, M Serena Lo Piccolo, Brian H Kushner, et al.
JAMA Oncology
|
October 17, 2018
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial
Brian H Kushner, Irene Y Cheung, Shakeel Modak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2006
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
Nai-Kong V Cheung, Rebecca Sowers, Andrew J Vickers, et al.
Cancer
|
May 2, 2013
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody
Brian H Kushner, Shakeel Modak, Ellen M Basu, et al.
Cancer
|
September 7, 2012
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature
Brian H Kushner, Shakeel Modak, Kim Kramer, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 103) with videos related to
Sort By:
Page
of 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2004
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma
Brian H Kushner, Kim Kramer, Michael P LaQuaglia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2003
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy
Brian H Kushner, Samuel D J Yeh, Kim Kramer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2014
Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission
Brian H Kushner, Irene Y Cheung, Shakeel Modak, et al.
Cancer
|
July 13, 2002
Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8
Irene Y Cheung, M Serena Lo Piccolo, Nancy Collins, et al.
Oncoimmunology
|
June 27, 2013
Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-<i>D</i>-glucan: A Phase I study in patients with chemoresistant neuroblastoma
Shakeel Modak, Brian H Kushner, Kim Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2003
Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma
Irene Y Cheung, M Serena Lo Piccolo, Brian H Kushner, et al.
JAMA Oncology
|
October 17, 2018
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial
Brian H Kushner, Irene Y Cheung, Shakeel Modak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2006
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
Nai-Kong V Cheung, Rebecca Sowers, Andrew J Vickers, et al.
Cancer
|
May 2, 2013
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody
Brian H Kushner, Shakeel Modak, Ellen M Basu, et al.
Cancer
|
September 7, 2012
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature
Brian H Kushner, Shakeel Modak, Kim Kramer, et al.
Page
of 11